Mastocytosis Clinical Trials and Treatments

Mastocytosis is a clonal myeloproliferative disorder characterized by accumulation and proliferation of abnormal mast cells in bone marrow, skin, and other organs. Most cases involve KIT proto-oncogene mutations (D816V) that drive mast cell expansion. Cutaneous mastocytosis (urticaria pigmentosa) is the most common form, particularly in children, characterized by brown lesions on skin that urticariate when irritated.

The most common symptoms of Mastocytosis include Flushing, pruritus (itching), and urticaria, Abdominal pain, diarrhea, and nausea, Anaphylactic reactions triggered by food, insect venom, or medications, Headaches, Bone pain or pathologic fractures from bone marrow involvement, among others. Mastocytosis affects approximately 1 in 10,000 to 1 in 300,000 (estimates vary widely). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Mastocytosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Targeted therapies have transformed the outlook for systemic mastocytosis, with tyrosine kinase inhibitors that block the KIT D816V mutation showing remarkable effectiveness at controlling mast cell proliferation. Newer agents in development aim to be even more selective, reducing side effects while maintaining strong disease control.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Mastocytosis. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

Mastocytosis arises from acquired (somatic) genetic changes in the affected cells, commonly involving KIT, rather than from an inherited variant. Most systemic mastocytosis carries an acquired (somatic) activating KIT variant tested in blood or bone marrow; it is not inherited. Additional somatic variants (e.g. TET2, SRSF2, ASXL1, RUNX1) mark more aggressive disease. The condition affects approximately 1 in 10,000 to 1 in 300,000 (estimates vary widely).

For Mastocytosis the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for KIT. Most systemic mastocytosis carries an acquired (somatic) activating KIT variant tested in blood or bone marrow; it is not inherited. Additional somatic variants (e.g. TET2, SRSF2, ASXL1, RUNX1) mark more aggressive disease.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Mastocytosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Mastocytosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.